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Abstract
Background: Lumefantrine (benflumetol) is a fluorene derivative belonging to the aryl amino alcohol class of anti-
malarial drugs and is commercially available in fixed combination products with b-artemether. Impurity
characterization of such drugs, which are widely consumed in tropical countries for malaria control programmes, is
of paramount importance. However, until now, no exhaustive impurity profile of lumefantrine has been established,
encompassing process-related and degradation impurities in active pharmaceutical ingredients (APIs) and finished
pharmaceutical products (FPPs).
Methods: Using HPLC-DAD/UV-ESI/ion trap/MS, a comprehensive impurity profile was established based upon
analysis of market samples as well as stress, accelerated and long-term stability results. In-silico toxicological
predictions for these lumefantrine related impurities were made using Toxtree® and Derek®.
Results: Several new impurities are identified, of which the desbenzylketo derivative (DBK) is proposed as a new
specified degradant. DBK and the remaining unspecified lumefantrine related impurities are predicted, using
Toxtree® and Derek®, to have a toxicity risk comparable to the toxicity risk of the API lumefantrine itself.
Conclusions: From unstressed, stressed and accelerated stability samples of lumefantrine API and FPPs, nine
compounds were detected and characterized to be lumefantrine related impurities. One new lumefantrine related
compound, DBK, was identified and characterized as a specified degradation impurity of lumefantrine in real
market samples (FPPs). The in-silico toxicological investigation (Toxtree® and Derek®) indicated overall a toxicity risk
for lumefantrine related impurities comparable to that of the API lumefantrine itself.
Background
Lumefantrine (benflumetol) is a 2,4,7,9-substituted
fluorene (2,3-benzindene) derivative (Figure 1). It was
synthesized in the 1970s by the Academy of Military
Medical Sciences, in Beijing, and registered in China
for anti-malarial use in 1987. It is now commercially
available in fixed combination products, mostly with b-
artemether (ACT, artemisinin-based combination ther-
apy), which are proven to be highly efficacious for
treatment of uncomplicated falciparum malaria. In
addition to the compound itself, the compound proved
to possess marked blood schizontocidal activity against
a wide range of Plasmodium, among them chloro-
quine-resistant Plasmodium falciparum [1-5].
Biochemical studies suggest that its anti-malarial
effect involves lysosomal trapping of the drug in the
food vacuole of the intra-erythrocytic parasite, followed
by binding to haem that is produced in the course of
haemoglobin digestion. This binding prevents the poly-
merization of haem into haemozoin, hence inhibiting
the detoxification of haem. Investigations involving
aryl-methanol compounds have suggested the coordi-
nation of the iron centre of haem (Fe(III)PPIX) and
related porphyrins by the alcohol functionality, indicat-
ing the structural activity relationship of the anti-
malarial drug lumefantrine [6]. Hence, structural
analogues of lumefantrine also posses marked anti-
malarial effects. Halofantrine, an aryl amino alcohol
analogue of lumefantrine, is also an anti-malarial drug,
but is known to be potentially cardiotoxic [7].
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Monodesbutyl-benflumetol, a metabolite of lumefan-
trine, exerts higher blood schizontocidal activity in
Plasmodium falciparum, as well as in Plasmodium
vivax. It is about 10-times more effective then lume-
fantrine [8]. The secondary alcohol permits the forma-
tion of dextrorotatory and levorotatory lumefantrine
enantiomers and routine synthesis yield the racemate
of (+)-lumefantrine and (-)-lumefantrine, which have
almost identical potency. Therefore, from the activity
point of view, there is no reason to use only one of the
enantiomers of lumefantrine instead of the racemate.
Moreover, in view of the low animal and human toxi-
city of the lumefantrine racemate, no major toxicologi-
cal differences between the two enantiomers are
expected [9]. However, other impurities resulting from
synthesis might be present.
Lumefantrine containing combinations are incorpo-
rated in the WHO essential drug list for the treatment
of malaria in endemic areas of the tropical climate. Due
to the logistic system [10], degradation products may be
spontaneously generated during distribution and storage.
Control of such impurities in drug substances and fin-
ished drug products is required as they might impart
different efficacy and bioavailability to the drug and/or
they might produce different adverse and toxic effects to
the patients [11].
The safety of a drug product is dependent not only on
the toxicological properties of the active drug substance,
but also on the toxicological properties of its impurities
[12]. Thus, there is an ever-increasing interest in impu-
rities present in APIs and FPPs [13]. Impurity profiling
(i.e. the identity as well as the quantity of impurities in
the pharmaceutical drug) is now gaining critical atten-
tion from regulatory authorities. The different Pharma-
copoeias, such as the European Pharmacopoeia (Ph.
Eur.), United States Pharmacopeia (USP) and Interna-
tional Pharmacopoeia (Ph.Int.) are incorporating specifi-
cation limits to acceptable levels of impurities present in
the API’s or FPPs formulations, based upon found levels
in approved market samples [11,14,15]. Moreover, ICH
guideline Q3A(R) stipulates different thresholds or
action limits based upon the maximum daily dose
(MDD). For lumefantrine formulations (FPP), with a
MDD of 960 mg/day, these are defined as 0.10% report-
ing threshold, 0.20% identification threshold and 0.20%
qualification threshold [16].
USP Salmous (Standards for Articles Legally Mar-
keted Outside the US) and Ph. Int. have already estab-
lished specification limits for three lumefantrine
related impurities: lumefantrine related compound A
((RS,Z)-2-(Dibutylamino)-2-(2,7-dichloro-9-(4-chloro-
benzylidene)-9H-fluoren-4-yl)ethanol), lumefantrine
related compound BA ((1S,3R,5R)-1,3-bis((EZ)-2,7-
Dichloro-9-(4-chlorobenzylidene)-9H-fluoren-4-yl)-2,6-
dioxabicyclo[3.1.0]hexane) and lumefantrine related
compound BB ((2-((EZ)-2,6-Dichloro-9-(4-chlorobenzy-
lidene)-9H-fluoren-4-yl)-3’-((EZ)-2,7-dichloro-9-(4-
chlorobenzylidene)-9H-fluoren-4-yl)-2,2’-bioxirane).
The USP Salmous specification limits of these impuri-
ties are 0.1% for both impurities A and BA and 0.3%
for impurity BB [17]. The Ph.Int. lumefantrine mono-
graph lists the same three compounds as identified
potential impurities, with specification limits of 0.1%
for impurity A and 0.3% for impurity BA and BB [18].
Analytical procedures have been reported for the assay
of lumefantrine in different FPPs, using HPLC-UV
[19-22]. Furthermore, an LC/MS/MS bio-analytical
method for quantification of lumefantrine in human
plasma has been developed [23]. However, no impurity
profile has been established for this drug, while this is
considered much more critical than the assay value. In
this study, the potential impurities are described, includ-
ing new degradants, as well as their relevance towards
specification settings and in-silico toxicological evalua-
tion. APIs and FPPs containing lumefantrine were evalu-
ated by HPLC, with UV detection for quantification and
with ESI-iontrap MS detection for identification.
Methods
Samples and chemicals
All drug substance batches (APIs), commercially avail-
able FPPs (Co-Artesiane®, Artefan®, Lumartem® and
Coartem®) and the standard of desbenzylketo (DBK)
lumefantrine derivative were supplied by Dafra Pharma
International (Belgium). USP-Salmous standards of
lumefantrine and impurity A were purchased from U.S.
Pharmacopeia (Basel, Switzerland). Analytical solutions
were prepared in HPLC grade tetrahydrofuran (Fisher
Scientific, Leicestershire, UK) at a concentration of 0.96
mg/ml lumefantrine, which corresponds to 100% label
claim (l.c.). A dilution equivalent to 0.5% l.c. is also pre-
pared and used for the quantification of the related
impurities. Hydrogen peroxide (H2O2), sodium hydro-
xide (NaOH) and ammonium acetate were purchased
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Figure 1 Structure of Lumefantrine.
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from Merck (Darmstadt, Germany), hydrochloric acid
(HCl) from Sigma-Aldrich (St Louis, USA) and glacial
acetic acid from Riedel-de Haën (Seelze, Germany). Sar-
torius (Göttingen, Germany) ultrapure 18.2 MΩ.cm
quality water and HPLC grade acetonitril (Romil,
Cambridge, UK) were used for HPLC-UV/MS analysis.
Liquid chromatography
HPLC-UV investigation of the impurity profiles was per-
formed on a HPLC-PDA apparatus consisting of a
Waters Alliance 2695 separation module and a Waters
2998 photodiode array detector with Empower 2 soft-
ware for data acquisition (all Waters, Milford, MA,
USA). For PDA detection, the UV spectrum was
recorded at 190-400 nm. Quantification was performed
at 266 nm. The positive ion ESI and the collision-
induced dissociation (CID) mass spectra were obtained
from the LC-UV/MS apparatus consisting of a Spectra
System SN4000 interface, a Spectra System SCM1000
degasser, a Spectra System P1000XR pump, a Spectra
System AS3000 autosampler, and a Finnigan LCQ Clas-
sic ion trap mass spectrometer in positive ion mode (all
Thermo, San José, CA, USA), mass to charge range m/z
100 to m/z 2000 at unit resolution and with a peak
width of 0.25 daltons/z, equipped with a Waters 2487
dual wavelength UV detector (Waters, Milford, MA,
USA) and Xcalibur 2.0 software (Thermo) for data
acquisition. ESI was conducted using a needle voltage of
4.5 kV. Nitrogen was used as sheath and auxiliary gas
with the heated capillary set at 250°C. UV-detection was
used for quantification (at 266 nm), while ESI-ion trap
MS detection was used for identification.
LC determination of impurities in lumefantrine sam-
ples was performed using a Purospher STAR RP-18
endcapped (150 × 4.6 mm, 5 μm particle size) column
(Merck, Darmstadt, Germany) with guard column at
30°C under isocratic conditions with a mobile phase
consisting of ammonium acetate (pH 4.9; 0.1 M) and
acetonitrile (10:90, v/v). The flow rate was set at 2.0
mL/min (minimal run time: 30 min.). The injection
volume was 10 μl. Under these conditions, lumefan-
trine elutes at approximately 22 min. System suitability
tests (SSTs) were established as the plate number on
lumefantrine (N ≥ 8.2 × 103) and the oxidative stress
degradation product (N ≥ 2.4 × 103), the signal-to-
noise ratio of 0.5% l.c. lumefantrine solution (S/N ≥
30), the peak area ratio of the 0.5% l.c. versus 100% l.c.
(between 0.4 and 0.6) and the relative position of the
in-situ prepared N-oxide by H2O2 treatment (RRT
between 0.12 and 0.22).
The LC method was validated for the determination of
lumefantrine and its related impurities. The selectivity of
the developed chromatographic method was established
by the separation of lumefantrine and its impurities. A
correlation coefficient (r2) of 0.9998 for lumefantrine
(0.0006 to 0.01 mg/ml) and 1.0 for impurity A and DBK
(0.001 to 0.1 mg/ml) demonstrated that the HPLC
method is linear in the lower range. LOD/LOQ values
for lumefantrine, DBK and impurity A were calculated
(S/N = 3 resp. 10): 0.004 mg/ml and 0.026 mg/ml
for lumefantrine (0.004% respectively 0.026% l.c.),
0.011 mg/ml and 0.040 mg/ml for DBK (0.012% respec-
tively 0.042% l.c.) and 0.110 mg/ml and 0.393 mg/ml for
impurity A (0.115% respectively 0.409% l.c.). The analy-
tical stability of lumefantrine, impurity A and DBK was
confirmed over a storage period of 24 hours at 5°C, i.e.
the sample compartment temperature. Accuracy and
precision were evaluated by repeated analysis (n = 6),
with 102.6% l.c. recovery and 2.1%, respectively 2.86%,
for repeatability, respectively intermediate precision.
The relative retention time (RRT) is defined as the
ratio of the retention time of the compound versus the
retention time of lumefantrine. The relative response
factor is defined as the ratio of the area of the com-
pound versus the area of lumefantrine, both injected at
the same concentration.
Forced degradation
Forced degradation of lumefantrine API and FPP was
performed under heat, light, acidic, alkaline and oxida-
tive stress conditions. In heat stress studies, the FPP
powder (one gram) was incubated at 40, 50 and 60°C
for respectively four, three and two days. The placebo
powder (one gram) was incubated for two days at 60°C.
In light stress studies, the FPP and placebo powder (one
gram) were subjected to UV (three days incubation) and
VIS (seven days incubation) light in a qualified Pharma
500 L stability cabinet (Weiss Technik) according to
ICH. Finally, FPP and placebo were stressed by adding
10 ml of 1 M HCl (acidic), 1 M NaOH (alkaline) or 1%
H2O2 (oxidative) to one gram of the powder to be
examined. Samples were incubated, up to eight days, at
5, 25, 40, 50 and 60°C. After the incubation, samples
were neutralized using NaOH (acidic), HCl (alkaline) or
Na2S2O5 (oxidative), and the solvent evaporated using
freeze-drying. The resulting powdered samples were dis-
persed in THF, centrifuged, HPLC-filtrated and analyzed
using HPLC-DAD/UV-ESI/MS.
Additionally, different batches of FPP were included in
long-term (up to 24 months, 30°C, 70-75% RH) and
accelerated (up to 6 months, 40°C, 75% RH) stability
studies according to ICH stability guidelines [24].
In-silico toxicological predictions
To make in-silico toxicological predictions for lumefan-
trine and its identified related impurities, two sources of
toxicological predictions were used: Derek® (Nexus
v2.0) for Windows developed by Lhasa Limited (Leeds,
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UK) and Toxtree® (v1.60) developed by Ideaconsult Ltd.
(Sofia, Bulgaria). Derek® (Nexus v2.0) for Windows is
an expert knowledge base system, containing descrip-
tions of molecular substructures which have been asso-
ciated with toxic endpoints (structural alerts), that
predicts whether a chemical is toxic in humans, other
mammals and bacteria. The programme applies struc-
ture-activity relationships ((Q)SARs) and other expert
knowledge rules to derive a reasoned conclusion about
the potential toxicity of the query chemical [25,26]. Tox-
tree® is an open source application, which is able to
estimate toxic hazards by applying a decision tree
approach and making structure-based predictions for a
number of toxicological endpoints using different mod-
ules. Hazard estimations were generated using three
Toxtree® modules: Cramer rules with extensions,
Benigni/Bossa rulebase and structure alerts for the in
vivo micronucleus assay in rodents.
Results and discussion
HPLC analysis of lumefantrine containing samples
As the Ph.Int./USP Salmous HPLC methods [17,18] are
a complex, step-wise gradient using an ion-pairing
reagent, this method is not compatible with MS detec-
tion. Moreover, the gradient is required for the detec-
tion of synthesis impurities BA and BB, which are
structurally very different from lumefantrine and its
other impurities, especially degradants. Therefore, an
isocratic RP-HPLC method was used without an MS-
incompatible ion-pairing reagent. The chromatographic
characteristics of these two synthesis impurities on this
system could not be evaluated, due to the unavailability
of references for these impurities.
Lumefantrine API and FPPs were exposed to diverse
stress conditions for different periods. Additionally, FPPs
were put on long-term and accelerated stability studies as
well according to ICH. FPP samples in the long-term sta-
bility study were kept for up to twenty-four months at
30°C/75% RH. In the accelerated study, the stability con-
ditions were adjusted and FPP samples were kept for up
to six months at 40°C/75% RH. The unstressed and
stressed API samples, as well as the unstressed (release),
accelerated, long-term and stressed FPP samples were
analyzed with the validated HPLC method. Five synthesis
and four stress related lumefantrine impurities have been
observed in lumefantrine containing samples (Table 1).
The relative retention time (RRT), relative to lumefan-
trine, of these impurities was defined and normalized
quantification was performed with a reporting threshold
of 0.10%. Maximal actually observed levels of lumefan-
trine related impurities in different samples under differ-
ent conditions were obtained (Table 2). None of these
lumefantrine related impurities were observed above the
reporting threshold (i.e. > 0.10%) in unstressed API and
release (T0) FPP samples, except for the monodesbutyl
derivative. However, these lumefantrine degradants were
observed in stressed API and FPP samples, and in FPP
stability studies. Compounds 1,2 and 3 were observed in
oxidative stressed API samples. Three lumefantrine
related impurities were observed in stressed FPP stability
Table 1 Structural information for the observed and/or reported lumefantrine related impurities
# Compound [formula, mono-isotopic mass] Structure Origin
1 Desbenzylketo N-oxide [C23H27NO3Cl2, MW 435.14] Alkaline stress
Oxidative stress
2 Lumefantrine (mono-)desbutyl derivative [C26H24NOCl3, MW 473.09] Oxidative stress
Metabolite
3 Lumefantrine N-oxide [C30H32NO2Cl3, MW 543.15] Oxidative stress
Degradation
4 2,7-dichloro-4-[2-(di-n-butylamino)-1-hydroxyethyl]-9H-fluoren-9-one; Desbenzylketo derivative (DBK) [C23H27NO2Cl2,
MW 419.14]
Oxidative stress
Acidic stress
Degradation
5 2-(di-n-butylamino)-1-[2,7-dichloro-9H-fluoren-4-yl]ethanol; Desbenzyl derivative [C23H29NOCl2, 405.16] Synthesis
6 Synthesis impurity found in lumefantrine API; Lumefantrine oxide [C30H32NO2Cl3, MW 543.14] Synthesis
7 Synthesis impurity found in lumefantrine API; Lumefantrine oxide [C30H32NO2Cl3, MW 543.14] Synthesis
8 (RS,Z)-2-(Dibutylamino)-2-(2,7-dichloro-9-(4-chloro-benzylidene)-9H-fluoren-4-yl)ethanol (isomeric compound);
Impurity A (Ph. Int./USP Salmous) [C30H32NOCl3, MW 527.15]
Synthesis
9 Synthesis impurity found in lumefantrine API; Lumefantrine oxide [C30H32NO2Cl3, MW 543.14] Synthesis
10 (1S,3R,5R)-1,3-bis((EZ)-2,7-Dichloro-9-(4-chlorobenzyl-idene)-9H-fluoren-4-yl)-2,6-dioxabicyclo[3.1.0]hexane; Impurity BA
(USP Salmous) [C44H24Cl6O2, 797.39]
Synthesis
11 2-((EZ)-2,6-Dichloro-9- (4-chlorobenzylidene)-9H-fluoren-4-yl)-3’-((EZ)-2,7-dichloro-9-(4-chlorobenzylidene)-9H-fluoren-
4-yl)-2,2’-bioxirane; Impurity BB (USP Salmous) [C44H24Cl6O2, 797.39]
Synthesis
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samples: compound 1 (60°C, 1 M NaOH, T2d), com-
pound 3 (60°C, 1% H2O2, T2d) and compound 4 (50°C, 1
M HCl, T3d). Compound 3 and 4 were also detected in
the accelerated (40°C/75% RH, T6m) and long-term stabi-
lity studies. A typical UV chromatogram illustrating the
separation of lumefantrine N-oxide, DBK, desbenzyl
lumefantrine derivative and lumefantrine is given in
Figure 2.
Identification of lumefantrine impurities with LC-MS/MS
The observed lumefantrine impurity peaks (related to
synthesis as well as degradation processes) in stressed
Table 2 Percentage maximum actual levels of lumefantrine related impurities observed(1)
# Compound API FPP
Unstressed Stressed Release Accelerated Stressed
1 Desbenzylketo N-oxide 1.39 0.60
2 Monodesbutyl derivative 0.56 0.11
3 Lumefantrine N-oxide 21.32 0.12 0.86
4 Desbenzylketo derivative 0.34 4.26
5 Desbenzyl derivative
6 Lumefantrine oxide (RRT ~ 0.49)
7 Lumefantrine oxide (RRT ~ 0.52)
8 Impurity A
9 Lumefantrine oxide (RRT ~ 0.59)
(1) RT: reporting threshold = 0.10%.
L 
4 
5 
3 
Figure 2 UV chromatogram of a mixed sample illustrating lumefantrine N-oxide, lumefantrine DBK and desbenzyl derivative and
lumefantrine. UV chromatogram of a mixed sample illustrating lumefantrine N-oxide (3), DBK (4) and desbenzyl lumefantrine derivative (5) and
lumefantrine (L).
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or unstressed API and FPPs were identified using LC-
MS/MS, with one of them investigated for the first
time and proposed as a new specified lumefantrine
related impurity. The desbutyl, desbenzyl and isomeric
compound A derivatives are already known lumefan-
trine impurities. The analytical characteristics of the
remaining unidentified lumefantrine related impurities
were obtained by analysis of MS data: m/z values
(Table 3), isotopic-distributions in mass spectra (Fig-
ure 2) and MS/MS (fragmentation pattern for struc-
tural identification).
The mono-isotopic mass of lumefantrine [(1RS)-2-
(Dibutylamino)-1-[(Z)-2,7-dichloro-9-(4-chlorobenzyli-
dene)-9H-fluoren-4-yl]ethanol] was calculated to be
527.15. The mass spectrum of lumefantrine main peak
indicated the most abundant ion at an m/z-ratio of
528.10, with an isotopic distribution corresponding to
the three chlorine atoms in its structure (35Cl at 75.77%
and 37Cl at 24.23%). In the mass spectrum of compound
1 (RRT ~ 0.08), 436.14 is observed to be the most abun-
dant m/z. The isotopic distribution is suggestive for a
compound possessing two chlorine atoms, and is identi-
cal to the isotopic distribution of compound 4. The
most abundant m/z value for compound 4 is 420.13,
with a molecular formula of C23H27NO2Cl2, i.e. desben-
zylketo derivative (DBK). This MS-derived structure was
confirmed by chemical synthesis of a DBK reference and
its IR and NMR spectroscopic structure confirmation.
This DBK reference standard gave similar chromato-
graphic retention characteristics as well as DAD-UV
spectrum as degradant 4 found in the samples. Based on
the observed m/z values of compound 1 and DBK, com-
pound 1 has an additional oxide to its structure, and is
thus assigned as being the N-oxide of DBK. The most
abundant ion found for compound 2 was m/z 474.00.
Its isotopic distribution is characteristic for a compound
possessing three chlorines and the molecular formula
C26H24NOCl3, i.e. the monodesbutyl derivative. As this
compound is more hydrophilic than lumefantrine, it
elutes much earlier than lumefantrine. Compound 3 was
found in the oxidative stressed FPP samples. Its most
abundant m/z is 544.08, with an isotopic distribution
corresponding to that of lumefantrine, giving the mole-
cular formula C30H24NO2Cl3. Based on the observed m/
z values of compound 3 and lumefantrine, compound 3
has an additional oxide to its structure. MS/MS frag-
mentation spectra, by collision induced dissociation
(CID, energy 100 eV), of compound 3 showed peaks at
m/z 526.12 (loss of H2O), 470.10, 396.99, 380.95, 346.23,
305.58, 298.06 (loss of C14H7Cl2) and 152.30. This
impurity was thus identified as lumefantrine N-oxide.
Compounds 6,7 and 9 gave identical mass spectra (Fig-
ure 3) with the most abundant ion found at m/z 544.12.
The isotopic distributions are characteristic for a com-
pound containing three chlorines and a molecular for-
mula C30H32NO2Cl3, i.e. oxides of lumefantrine. As
these three impurities are eluting at different retention
time, they are most probably isomeric compounds with
an -OH function at different positions on the lumefan-
trine aromatic ring structure.
Specified lumefantrine impurity DBK
The lumefantrine-related compound 4, DBK (RRT ~
0.33), was not only formed in stress stability samples,
but was also observed in accelerated and stressed stabi-
lity samples of FPP. Moreover, DBK was found to be
present in market samples at a concentration ranging
between 0.03% and 0.12%, determined by area normali-
zation. Subsequently, DBK was synthesized for further
analytical characterization, including confirmation of its
relative retention time (RRT) and determination of its
relative response factor (RFF) at the detection wave-
length of 266 nm. The RRT and the RRF of DBK rela-
tive to lumefantrine were experimentally determined to
be 0.33 and 2.87 respectively. The DAD-UV spectra
recorded for lumefantrine and DBK (Figure 4) showed
the wavelength of maximum absorption to be higher for
DBK (app. 266 nm) than for lumefantrine (app.
234 nm), due to the benzyl group being replaced by the
keto function. This impurity was observed in oxidative
and acidic stress degradation, as well as in the acceler-
ated and long-term ICH stability studies, justifying this
degradant to be classified as a specified degradant.
In-silico toxicological predictions of lumefantrine and its
related impurities
Using the knowledge-based expert systems Toxtree® and
Derek®, general toxicological and carcinogenic alerts for
lumefantrine, as well as for its related observed and
already described impurities, have been investigated.
Since DBK is a specified lumefantrine-related compound,
Table 3 HPLC characteristics of lumefantrine related
impurities
# Compound RT(1) RRT(2) Most abundant
m/z observed
1 Desbenzylketo N-oxide 1.79 0.08 436.14
2 Monodesbutyl derivative 3.25 0.15 474.00
3 Lumefantrine N-oxide 3.96 0.17 544.08
4 Desbenzylketo derivative 7.41 0.33 420.13
5 Desbenzyl derivative 7.69 0.34 406.09
6 Lumefantrine oxide 10.96 0.49 544.12
7 Lumefantrine oxide 11.45 0.52 544.12
8 Impurity A 12.70 0.58 528.10
9 Lumefantrine oxide 12.97 0.59 544.12
L Lumefantrine 22.28 1.00 528.10
(1) Retention time (min.).
(2) Relative retention time.
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(1) (2) (3) 
  
(4) (5) (6,7,9) 
 
 
(8)   
m/z 436.10 m/z 474.00 m/z 544.08 
m/z 420.13 m/z 406.09 m/z 544.12 
m/z 528.10 
Figure 3 Isotopic-distribution mass spectra of lumefantrine related impurities with the most abundant m/z observed. Isotopic-
distribution mass spectra of lumefantrine related impurities: (1) Desbenzylketo N-oxide; (2) Monodesbutyl derivative; (3) Lumefantrine N-oxide;
(4) Desbenzylketo derivative; (5) Desbenzyl derivative; (6,7,9) Oxide of lumefantrine and (8) Impurity A (USP/Ph.Int).
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the toxicity profile of DBK is of paramount importance.
Based on the Cramer rules with extensions, Toxtree®
clearly predicted general toxicity risks (class III), and gen-
otoxic alerts (polycyclic aromatic hydrocarbons, haloge-
nated benzene and H-acceptor-path3-H-acceptor) for
DBK, which are identical to the API lumefantrine itself.
According to the toxicological concern (TTC), the daily
dosage for compounds classified in class III should be
below 90 μg/person (60 kg)/day to be validated as non
toxic [27]. Hence, the TTC value of 90 μg on the MDD
of 960 mg lumefantrine corresponds to a limit of 0.01%
(90 μg/960 mg), which is far below the levels actually
observed.
The toxicity profile by Derek® of DBK is defined by
several general toxicity alerts which are similar to lume-
fantrine: hERG channel inhibion and a2 μ-globulin
nephropathy [28] plus additional photo-toxicity and
-allergenicity. However, Derek® did not trigger any gen-
otoxicity or carcinogenicity for DBK.
The other lumefantrine related impurities were also
predicted in Toxtree® to have a high general toxicity
similar to lumefantrine itself (depicted Class III), based
on the Cramer rules with extensions, and genotoxicity
risks. Again, Derek® clearly indicated a limit toxicity
profile for the majority of lumefantrine related impuri-
ties compared to lumefantrine (hERG channel inhibion,
a2μ-globulin nephropathy). Only impurity BB triggered
additional toxicity alerts (carcinogenicity/mutagenicity,
chromosome damage, eye/skin irritation, developmental
toxicity, skin sensitization), indicative for a non-toxic
profile compared to lumefantrine itself.
Conclusions
An exhaustive impurity profiling of lumefantrine was
performed using HPLC-UV/ESI-ion trap MS. From
unstressed, stressed and accelerated stability samples of
lumefantrine API and FPPs, nine compounds were
detected and characterized to be lumefantrine related
impurities. One new lumefantrine related compound,
DBK, was identified and characterized as a specified
degradation impurity of lumefantrine in real market
samples (FPPs). The in-silico toxicological investigation
(Toxtree® and Derek®) indicated overall a lesser toxicity
for the specified impurity DBK compared to the API
lumefantrine itself.
Acknowledgements
The authors would like to thank Dafra Pharmaceuticals (Turnhout, Belgium)
for the provision of the reference substances, as well as their interest and
support in this investigation. Moreover, one of the authors (SS) is supported
by the Epidemiology and Modeling Project within the Institutional University
Cooperation Programme (Jimma University) of VLIR.
Author details
1Drug Quality and Registration (DruQuaR) group, Faculty of Pharmaceutical
Sciences, Ghent University, Harelbekestraat 72, B-9000 Ghent, Belgium.
2Department of Physiology and Biometrics, Faculty of Veterinary Medicine,
Ghent University, Salisburylaan 133, B-9820 Merelbeke, Belgium. 3School of
Pharmacy, Jimma University, Jimma, Ethiopia. 4Foundation ACT-ion Afrique,
B-1000 Brussel, Belgium.
Authors’ contributions
MV and SS did part of the analytical experiments incl. validation, performed
the in-silico verification and wrote the article. BB, EVG and SVD did part of
the analytical experiments, incl. stability and MS experiments and QC on
data. CB and LD critically reviewed and discussed this manuscript. FHJ
designed the experiments, overviewed the DBK reference synthesis, and
critically reviewed the manuscript. BDS was the overall study director,
responsible for design of experiments, interpretation of data and writing this
manuscript. All authors read and approved the final manuscript.
Competing interests
The authors, MV, BB, EVG and BDS would like to acknowledge that Dafra
sponsored the analytical development. However, these authors do not work
for, or represent in any way, Dafra. FHJ is partly working for Dafra.
Received: 23 December 2010 Accepted: 28 February 2011
Published: 28 February 2011
References
1. Falade C, Makanga M, Premji Z, Ortmann CE, Stockmeyer M, de Palacios PI:
Efficacy and safety of artemether-lumefantrine (Coartem (R)) tablets (six-
dose regimen) in African infants and children with acute)
uncomplicated falciparum malaria. Trans R Soc Trop Med Hyg 2005,
99:459-467.
2. Hatz C, Abdulla S, Mull R, Schellenberg D, Gathmann I, Kibatala P, Beck HP,
Tanner M, Royce C: Efficacy and safety of CGP 56697 (artemether and
benflumetol) compared with chloroquine to treat acute falciparum
malaria in Tanzanian children aged 1-5 years. Trop Med Int Health 1998,
3:498-504.
Figure 4 UV spectra recorded for lumefantrine (left) and DBK (right) showing the observed wavelength of maximum absorption. DAD-
UV spectra of lumefantrine (left) and DBK (right).
Verbeken et al. Malaria Journal 2011, 10:51
http://www.malariajournal.com/content/10/1/51
Page 8 of 9
3. van Vugt M: Concerns about the privatization of public goods: A social
dilemma analysis. Soc Psychol Q 1997, 60(4):355-367.
4. van Vugt M, Looareesuwan S, Wilairatana P, McGready R, Villegas L,
Gathmann I, Mull R, Brockman A, White NJ, Nosten F: Artemether-
lumefantrine for the treatment of multidrug-resistant falciparum malaria.
Trans R Soc Trop Med Hyg 2000, 94:545-548.
5. vonSeidlein L, Jaffar S, Pinder M, Haywood M, Snounou G, Gemperli B,
Gathmann I, Royce C, Greenwood B: Treatment of African children with
uncomplicated falciparum malaria with a new antimalarial drug, CGP
56697. J Infect Dis 1997, 176:1113-1116.
6. de Villiers KA, Egan TJ: Recent advances in the discovery of haem-
targeting drugs for malaria and schistosomiasis. Molecules 2009,
14:2868-2887.
7. Traebert M, Dumotier B, Meister L, Hoffmann P, Dominguez-Estevez M,
Suter W: Inhibition of hERG K+ currents by antimalarial drugs in stably
transfected HEK293 cells. Eur J Pharmacol 2004, 484:41-48.
8. Pirker-Krassnig DK, Wernsdorfer G, Sirichaisinthop J, Rojanawatsirivet C,
Kollaritsch H, Wernsdorfer WH: Comparative study on the in vitro activity
of lumefantrine and desbutyl-benflumetol in fresh isolates of
Plasmodium vivax from Thailand. Wien Klin Wochenschr 2004, 116:47-52.
9. Wernsdorfer WH, Landgraf B, Kilimali V, Wernsdorfer G: Activity of
benflumetol and its enantiomers in fresh isolates of Plasmodium
falciparum from East Africa. Acta Trop 1998, 70:9-15.
10. Ballereau F, Prazuck T, Schrive I, Lafleuriel MT, Rozec D, Fisch A, Lafaix C:
Stability of essential drugs in the field: Results of a study conducted
over a two-year period in Burkina Faso. Am J Trop Med Hyg 1997,
57:31-36.
11. Bari SBKB, Jaiswal YS, Shikhedkar AA: Impurity profile: Significance in
active pharmaceutical ingredient. Eurasian J Anal Chem 2007,
2(1):32-53.
12. Vergote V, Burvenich C, Van de Wiele C, De Spiegeleer B: Quality
specifications for peptide drugs: a regulatory-pharmaceutical approach. J
Pept Sci 2009, 15:697-710.
13. De Spiegeleer B, Vergote V, Pezeshki A, Peremans K, Burvenich C: Impurity
profiling quality control testing of synthetic peptides using liquid
chromatography-photodiode array-fluorescence and liquid
chromatography-electrospray ionization-mass spectrometry: The
obestatin case. Anal Biochem 2008, 376:229-234.
14. Nicolas EC, Scholz TH: Active drug substance impurity profiling - Part I.
LC/UV diode array spectral matching. J Pharm Biomed Anal 1998,
16:813-824.
15. Roy J: Pharmaceutical impurities - A mini review. AAPS PharmSciTech
2002, 3:article 6.
16. ICH guidelines - International Conference on Harmonization, Q3A(R2)
Impurities in new drug substances CPMP/ICH/2737/99. (October 2006).
[http://www.ema.europa.eu/docs/en_GB/document_library/
Scientific_guideline/2009/09/WC500002675.pdf], [Accessed on 5 November
2010 at 11:06].
17. Authorized Lumefantrine USP Salmous Standard (Februari 2009). [http://
www.usp.org/pdf/EN/nonUSStandards/lumefantrine.pdf], [Accessed on 24
October 2010 at 17:14].
18. Lumefantrine: Document QAS/06.186/FINAL (WHO Ph. Int. - July 2008).
[http://www.who.int/medicines/publications/pharmacopoeia/
Lumef_monoFINALQAS06_186_July08.pdf], [Accessed on 24 October 2010
at 17:37].
19. Lee H: Pharmaceutical applications of liquid chromatography coupled
with mass spectrometry (LC/MS). J Liq Chromatogr Relat Technol 2005,
28:1161-1202.
20. Cesar ID, Nogueira FHA, Pianetti GA: Simultaneous determination of
artemether and lumefantrine in fixed dose combination tablets by HPLC
with UV detection. J Pharm Biomed Anal 2008, 48:951-954.
21. Cesar ID, Nogueira FHA, Pianetti GA: Comparison of HPLC, UV
spectrophotometry and potentiometric titration methods for the
determination of lumefantrine in pharmaceutical products. J Pharm
Biomed Anal 2008, 48:223-226.
22. Patil KR, Rane VP, Sangshetti JN, Shinde DB: A Stability-Indicating LC
Method for Lumefantrine. Chromatographia 2009, 69:375-379.
23. Munjal V, Paliwal N, Chaursia BK, Varshney B, Ahmed T, Paliwal J: LC-
tandem mass spectrometry method for quantification of lumefantrine in
human plasma and its application to bioequivalence study.
Chromatographia 2010, 71:505-510.
24. ICH guidelines - International Conference on Harmonization, Q1A(R2)
Stability testing of new drug substances and products CPMP/ICH/2736/
99. (August 2003). [http://www.ema.europa.eu/docs/en_GB/
document_library/Scientific_guideline/2009/09/WC500002651.pdf],
[Accessed on 5 November 2010 at 12:10].
25. Ellison CM, Madden JC, Judson P, Cronin MTD: Using in silico tools in a
weight of evidence approach to aid toxicological assessment. Mol Inf
2010, 29:97-110.
26. Mohan CG, Gandhi T, Garg D, Shinde R: Computer-assisted methods in
chemical toxicity prediction. Mini Rev Med Chem 2007, 7:499-507.
27. Munro IC, Renwick AG, Danielewska-Nikiel B: The threshold of toxicological
concern (TTC) in risk assessment. Toxicol Lett 2008, 180:151-156.
28. Kristiansen E, Madsen C: Induction of protein droplet (alpha(2-mu)-
globulin) nephropathy in male-rats after short-term dosage with 1,8-
cineole and L-limonene. Toxicol Lett 1995, 80:147-152.
doi:10.1186/1475-2875-10-51
Cite this article as: Verbeken et al.: Stability-indicating HPLC-DAD/UV-
ESI/MS impurity profiling of the anti-malarial drug lumefantrine. Malaria
Journal 2011 10:51.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Verbeken et al. Malaria Journal 2011, 10:51
http://www.malariajournal.com/content/10/1/51
Page 9 of 9
